Asylia Therapeutics has a total of 11 patents globally. Of these 11 patents, more than 90% patents are active. United States of America seems to be the main focused R&D centre and also is the origin country of Asylia Therapeutics.
Asylia Therapeutics was founded in 2019. Asylia Therapeutics specializes in developing innovative immune-modulating treatments for infectious, cancerous, and autoimmune disorders.
Do read about some of the most popular patents of Asylia Therapeutics which have been covered by us in this article and also you can find Asylia Therapeutics patents information, the worldwide patent filing activity and its patent filing trend over the years, and many other stats over Asylia Therapeutics patent portfolio.
How many patents does Asylia Therapeutics have?
Asylia Therapeutics has a total of 11 patents globally. These patents belong to 2 unique patent families. Out of 11 patents, 10 patents are active.
How Many Patents did Asylia Therapeutics File Every Year?
Are you wondering why there is a drop in patent filing for the last two years? It is because a patent application can take up to 18 months to get published. Certainly, it doesn’t suggest a decrease in the patent filing.
| Year of Patents Filing or Grant | Asylia Therapeutics Applications Filed | Asylia Therapeutics Patents Granted |
| 2022 | 2 | – |
| 2021 | 9 | – |
How many Asylia Therapeutics patents are Alive/Dead?
Worldwide Patents
How Many Patents did Asylia Therapeutics File in Different Countries?
Countries in which Asylia Therapeutics Filed Patents
| Country | Patent |
| India | 1 |
| Singapore | 1 |
| Canada | 1 |
| Korea (South) | 1 |
| China | 1 |
| United States Of America | 1 |
| Europe | 1 |
| Australia | 1 |
| Israel | 1 |
Where are Research Centers of Asylia Therapeutics Patents Located?
The Research Centre for all the Asylia Therapeutics patents is the United States of America.
List of Asylia Therapeutics patents
| Asylia Therapeutics Patents | Title |
| US20230128075A1 | Monoclonal Antibodies Targeting Hsp70 And Therapeutic Uses Thereof |
| EP4125946A2 | Monoclonal Antibodies Targeting Hsp70 And Therapeutic Uses Thereof |
| CN115667299A | Monoclonal Antibodies Targeting Hsp70 And Therapeutic Uses Thereof |
| WO2023056361A1 | Anti-Hsp70 Antibodies And Therapeutic Uses Thereof |
| AU2021241704A1 | Monoclonal Antibodies Targeting Hsp70 And Therapeutic Uses Thereof |
| CA3172949A1 | Monoclonal Antibodies Targeting Hsp70 And Therapeutic Uses Thereof |
| IL296755A | Monoclonal Antibodies Targeting Hsp70 And Therapeutic Uses Thereof |
| SG11202253266GA | Monoclonal Antibodies Targeting Hsp70 And Therapeutic Uses Thereof |
| IN202217060683A | Monoclonal Antibodies Targeting Hsp70 And Therapeutic Uses Thereof |
| KR1020230006477A | Monoclonal Antibodies Targeting Hsp70 And Their Therapeutic Uses |
| WO2021195557A3 | Monoclonal Antibodies Targeting Hsp70 And Therapeutic Uses Thereof |
What are Asylia Therapeutics key innovation segments?
What Technologies are Covered by Asylia Therapeutics?
The chart below distributes patents filed by Asylia Therapeutics